Prolonged stable disease in a uveal melanoma patient with germline MBD4 nonsense mutation treated with pembrolizumab and ipilimumab
- 4 February 2019
- journal article
- research article
- Published by Springer Nature in Immunogenetics
- Vol. 71 (5-6) , 433-436
Abstract
There is currently no effective treatment for metastasised uveal melanoma (UM). Recently, it was reported that a UM patient was responsive to checkpoint inhibitor (CI) treatment, due to a high tumour mutation burden correlated with a germline loss-of-function MBD4 mutation. Here, we report on another UM patient who carried an MBD4 germline nonsense variant (p.Leu563Ter) and her tumour showed a fivefold higher than average mutation burden. We confirmed the association between germline loss-of-function variant in MBD4 and CI response. The patient experienced stable disease (10 months) and survived 2 years with metastatic disease, which is twice as long as median survival. Additionally, the frequency of MBD4 loss-of-function variants in reported UM cohorts was > 20 times higher than in an aggregated population genome database (P < 5 × 10−5), implying a potential role as UM predisposition gene. These findings provide a strong basis for the inclusion of MBD4 in the screening of potential UM-prone families as well as stratification of immunotherapy.Keywords
Funding Information
- National Health and Medical Research Council (1093017, 1117663)
This publication has 17 references indexed in Scilit:
- Drug Combinations as the New Standard for Melanoma TreatmentCurrent Treatment Options in Oncology, 2016
- Analysis of protein-coding genetic variation in 60,706 humansNature, 2016
- Uveal melanoma as a target for immune-therapyAnnals of Translational Medicine, 2016
- Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4Oncotarget, 2015
- SF3B1 Mutations Are Associated with Alternative Splicing in Uveal MelanomaCancer Discovery, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3Nature Genetics, 2013
- Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanomaNature Genetics, 2013
- Personalized treatment of uveal melanomaEye, 2012
- The thymine glycosylase MBD4 can bind to the product of deamination at methylated CpG sitesNature, 1999